U.S. begins study on allergic reaction risk in Moderna, Pfizer vaccines
(Reuters) – The U.S. National Institutes of Health said on Wednesday it had begun a mid-stage study to determine the risk of allergic reactions to COVID-19 vaccines made by Moderna Inc and Pfizer Inc.
Several allergic reaction incidents, including serious episodes, known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.
In January, the U.S. Centers for Disease Control and Prevention said allergic reactions are occurring at a rate of 11.1 per 1 million vaccinations.
The study, funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults between the ages of 18 to 69, with about 60% participants having a history of severe allergic reactions to food, insect stings or immunotherapy.
The goal of the trial is to access the proportion of participants who have a systemic allergic reaction within 90 minutes after injection.
The agency expects to report data later this summer.
Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli, Bernard Orr
Our Standards: The Thomson Reuters Trust Principles.
disease control coronavirus covid-19 vaccine
- FDA Halts J&J COVID-19 Vaccine Manufacturing at Emergent BioSolutions That Had Contamination Issue April 19, 2021
- EU Purchases 100M More Doses of Pfizer/BioNTech COVID-19 Vaccine April 19, 2021
- From haute cuisine to hot dogs: How dining out has evolved over 200 years – and is innovating further in the pandemic April 19, 2021
- Democratic bill attempts to undo voter restrictions of past 15 years April 19, 2021
- Ivermectin: why a potential COVID treatment isn’t recommended for use April 19, 2021